接受米托坦治疗的肾上腺皮质癌患者椎体骨折的进展
这项多中心回顾性队列研究纳入2010年1月至2020年1月意大利和法国2个参考中心的肾上腺皮质癌患者,探讨米托坦联合或不联合化疗与形态学椎体骨折比例增加的关系。结果显示意大利队列椎体骨折频率从28.3%升至47.8%(P=.04),法国队列从17.8%升至35.6%(P=.04),椎体骨折进展比例分别为39.1%和28.9%。基线椎体骨折和高体重指数与椎体骨折进展独立相关,在72例晚期患者中椎体骨折进展与更差的生存相关。
要点
- 米托坦联合或不联合化疗的肾上腺皮质癌患者椎体骨折频率显著增加。
- 意大利和法国队列椎体骨折频率分别从28.3%升至47.8%、从17.8%升至35.6%。
- 基线椎体骨折和高体重指数与椎体骨折进展独立相关,而非皮质醇补充剂量。
核心结论
- 在肾上腺皮质癌患者中,米托坦联合或不联合化疗会损害骨骼健康,且这一作用独立于皮质醇补充。
- 应针对这些患者采取适当的预防措施以降低骨折风险。
研究设计与样本
- 多中心回顾性队列研究,纳入2010年1月至2020年1月在意大利和法国2个参考中心接受米托坦单药或联合化疗的肾上腺皮质癌患者。
主要发现
- 意大利队列椎体骨折频率在米托坦治疗前后分别为28.3%和47.8%(P=.04)。
- 法国队列椎体骨折频率在米托坦治疗前后分别为17.8%和35.6%(P=.04)。
- 意大利和法国队列中椎体骨折进展比例分别为39.1%和28.9%。
- 多因素分析显示基线椎体骨折和高体重指数与椎体骨折进展独立相关,而皮质醇补充剂量无此关联。
- 在72例晚期肾上腺皮质癌患者中,椎体骨折进展与更差的生存相关。
关键数值与推荐
- 意大利队列椎体骨折频率:治疗前28.3% vs 治疗后47.8%(P=.04)。
- 法国队列椎体骨折频率:治疗前17.8% vs 治疗后35.6%(P=.04)。
- 椎体骨折进展比例:意大利队列39.1%,法国队列28.9%。
临床怎么用
- 原文结论提出应针对接受米托坦治疗的肾上腺皮质癌患者采取适当的预防措施以降低骨折风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Patients with adrenocortical carcinoma (ACC) are frequently on mitotane therapy for a long time period. The drug exerts adrenolytic activity requiring glucocorticoid supplementation, which can be potentially detrimental for bone. OBJECTIVE: To explore whether mitotane with/without chemotherapy is associated with an increased proportion of morphometric vertebral fractures (VFs) in ACC patients. Secondary objectives were proportion of patients with VF progression, or worsening of the spinal deformity index (SDI) during mitotane therapy; and to explore predictive factors of VF progression and a prognostic role of VF progression. METHODS: Multicenter, retrospective cohort study of patients with ACC who received mitotane alone or in association to chemotherapy, recruited from January 2010 to January 2020 in 2 reference centers in Italy and France. RESULTS: A significant increase in the frequency of VFs before and after mitotane therapy was seen both in Italian (28.3% vs 47.8%, P = .04) and French (17.8% vs 35.6%, P = .04) series. VF progression was observed in 39.1%, and 28.9% of patients, respectively. Baseline VFs and increased patient body mass index, but not the dose of cortisol supplementation, showed an independent association with VF progression at multivariate analysis. Among the 72 advanced ACC patients, progression of VFs was associated with a poorer survival. CONCLUSION: The administration of mitotane with/without chemotherapy in ACC patients impairs bone health independently from cortisol supplementation. Appropriate preventive measures to decrease the fracture risk should be implemented in these patients.
引用
- Cosentini D, Grisanti S, Hadoux J, et al. Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. J Clin Endocrinol Metab. 2022. PMID: 34905056. doi:10.1210/clinem/dgab899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。